Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Aravive Receives IND Clearance for AVB-500 Trial for Clear Cell Renal Cell Carcinoma

americanpharmaceuticalreviewJanuary 17, 2020

Tag: IND , renal cell carcinoma , RCC , Aravive , AVB-500

PharmaSources Customer Service